{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}],"title":"Whole blood chimerism-Any"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}],"title":"Whole blood chimerism->=95% donor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}],"title":"T Cell chimerism-Any"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"T Cell chimerism>=95% donor"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"description":"Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue.","groups":[{"description":"Matched related donor (MRD) subjects receive Graft Vs Host Disease (GVHD )prophylaxis with Methotrexate alone Subjects also receive busulfan, fludarabine, and tacrolimus and may receive Alemtuzumab.\n\nMatched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus.","id":"OG000","title":"Experimental: GVHD Prophylaxis"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Because there were no differences in chimerism results as a function of either the immunosuppression used or busulfan dose received, the results are being reported only for the total population.","reportingStatus":"POSTED","timeFrame":"30 days post transplant","title":"Incidence of DNA Chimerism in Patients Between One Month Post Transplant","type":"SECONDARY","unitOfMeasure":"Participants"}